PDE5A and chronic obstructive pulmonary disease: Next to PDE5 inhibitors, PDE4 inhibitors like roflumilast (Daxas®, Nycomed, Zurich, Switzerland) have found therapeutic use as an oral drug to treat chronic obstructive pulmonary disease (COPD) [13].